Acumen Pharmaceuticals (Acumen Pharmaceuticals) Operating Cash Flow per Share : $-0.96 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Acumen Pharmaceuticals Operating Cash Flow per Share?

Acumen Pharmaceuticals's operating cash flow per share for the three months ended in Mar. 2024 was $-0.30. Acumen Pharmaceuticals's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.96.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -50.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Acumen Pharmaceuticals's Operating Cash Flow per Share or its related term are showing as below:

ABOS' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -53.8 Med: -52.15 Max: -50.5
Current: -50.5

During the past 5 years, Acumen Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was -50.50% per year. The lowest was -53.80% per year. And the median was -52.15% per year.

ABOS's 3-Year OCF Growth Rate is ranked worse than
89.47% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs ABOS: -50.50

Acumen Pharmaceuticals Operating Cash Flow per Share Historical Data

The historical data trend for Acumen Pharmaceuticals's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acumen Pharmaceuticals Operating Cash Flow per Share Chart

Acumen Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.24

-0.26

-0.90

-0.87

-0.89

Acumen Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial													-0.25	-0.28	-0.24	-0.14	-0.30

Competitive Comparison of Acumen Pharmaceuticals's Operating Cash Flow per Share

For the Biotechnology subindustry, Acumen Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acumen Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acumen Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Acumen Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.

Acumen Pharmaceuticals Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Acumen Pharmaceuticals's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-43.064	/	48.609
	=	-0.89

Acumen Pharmaceuticals's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-17.859	/	59.812
	=	-0.30

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.96

Acumen Pharmaceuticals Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Acumen Pharmaceuticals's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Acumen Pharmaceuticals (Acumen Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acumen Pharmaceuticals Inc (NAS:ABOS) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

427 Park Street, Charlottesville, VA, USA, 22902

Website

https://www.acumenpharm.com

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believe to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Executives

Daniel Joseph Oconnell	director, officer: President and CEO	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Derek M Meisner	officer: Chief Legal Office & Corp Sec	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Eric Siemers	officer: Chief Medical Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Russell Barton	officer: Chief Operating Officer	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Matt Zuga	officer: Chief Financial Officer	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Derrell Porter	director	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Stalfort John A Iii	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Robert D. Hardie	10 percent owner	210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Nathan B Fountain	director	C/O ACUMEN PHARMACEUTICALS, INC., 427 PARK STREET, CHARLOTTESVILLE VA 22902
Sands Capital Global Venture Fund Ii, L.p.	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209
Sands Capital Life Sciences Pulse Fund, Llc	10 percent owner	C/O SANDS CAPITAL VENTURES, LLC, 1000 WILSON BOULEVARD, SUITE 3000, ARLINGTON VA 22209